Chief Medical Officer Summit 2018

08:45 - 19:00, 5 Mar 18
Wellcome Collection, London
Print page

Conference

NEW TO 2018. This inaugural event, will define and address the unique challenges associated with managing Medical Affairs functions with limited resources.

The summit aims to enable CMO and R+D executives to understand possible routes for raising capital, partner with big Pharma, address and support the skills required to be a CMO in a SME and create a network to share ideas, solutions and support.

Regulatory considerations around innovation support, clinical trials and Brexit will also be debated.

Date

Monday 5 March 2018

Venue

Wellcome Collection
183 Euston Road
London
NW1 2BE
UK

Agenda

08:45 - 09:30 Registration, refreshments and networking

09:30 - 09:45 Welcome and scene setting

Steve Bates OBE, Chief Executive Officer, BioIndustry Association

09:45 - 10:05 Opening keynote address

Louise Wood, NIHR

10:05 - 11:00 The role of a Chief Medical Officer

The role of Chief Medical Officer (CMO) is evolving in response to the requirement for biotechnology and pharmaceutical companies to apply more ethical and scientific rigor to decision making, driven by both the public and the broader medical community. This session will explore this changing role from the point of view of the ‘Investor’, the ‘Regulator’ and the CMO him/herself.

Chairperson: Glen Clack, Honorary Professor of Translational Medicine, Department of Oncology and Metabolism, University of Sheffield

Panel and presentations

View from Investors – Hamish Cameron, SV Health Investors
View from a regulatory perspective – David Jefferys, Eisai
View from the coalface – Dr Penny Ward, Chief Medical Officer, Karus Therapeutics

11:00 - 11:30 Refreshments and networking

11:30 - 13:00 Essential skills

Effective Chief Medical Officers require a wide and varied skillset, resilience and adaptability. This session addresses methods to assist the acquisition, maintenance and improvement of skills to remain effective within the continuously evolving pharmaceutical environment.

Chairperson: Professor Alan Boyd, President, Faculty of Pharmaceutical Medicine

Panel Members

Dr Ian Mills
Dr Mike Perkins
Dr Kevin Bryett

Presentations on Postgraduate Training in Pharmaceutical Medicine and Revalidation followed by a Panel Discussion

13:00– 14:00 Lunch and networking

14:00 – 15:30 Regulatory considerations around innovation support, clinical trials and Brexit

This session will highlight the strength of the UK regulatory system, supporting innovation through the MHRA Innovation Office and Early Access to Medicines Scheme (EAMS). New EU clinical trials regulations and the implications of Brexit will also be discussed.

Chairperson: Steve Bates OBE, CEO, BioIndustry Association

Presentations and panel

MHRA support to innovation

Innovation Office – Ian Rees, MHRA
EAMS - Daniel O’Connor, MHRA
Funding for SMEs in EAMS – Ian Campbell, Director of Health & Life Sciences, IUK

Clinical trials regulation – Kirsty Wydenbach, MHRA

Revised EMA guideline on first-in-human clinical trials
New EU Clinical Trials Regulation
Brexit

15:30 - 16:00 Refreshments and networking

16:00 - 17:30 Partnering with Pharma and NHS

Finding and fostering effective partnerships is an essential element of life in a biotech company. This session explores ways to support effective partnering across the variety of situations likely to be encountered in the life of a biotech CMO.

Chairperson: Dr Penny Ward, Chief Medical Officer, Karus Therapeutics

Presentations and panel